Collegium Pharmaceutical (COLL) Net Income towards Common Stockholders Growth (5y) (2019 - 2026)
Powered by 
Analysis
Collegium Pharmaceutical (COLL) Net Income towards Common Stockholders Growth (5y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn |
| 10 | Collegium Pharmaceutical | 753.09 Mn | 603.77 Mn | 110.29 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.12% |
| Mar 31, 2026 | -2.94% |
| Dec 31, 2025 | 19.51% |
| Sep 30, 2025 | 22.79% |
| Jun 30, 2025 | 8.26% |
| Mar 31, 2025 | 39.96% |
| Dec 31, 2024 | 50.40% |
| Sep 30, 2024 | 28.68% |
| Jun 30, 2024 | 43.86% |
| Mar 31, 2024 | 37.17% |
| Dec 31, 2023 | 28.59% |
| Sep 30, 2023 | 26.59% |
| Jun 30, 2023 | 24.54% |
| Mar 31, 2023 | 1.35% |
| Dec 31, 2022 | 16.18% |
| Sep 30, 2022 | 15.26% |
| Jun 30, 2022 | 24.47% |
| Mar 31, 2022 | 10.75% |
| Dec 31, 2021 | 1.89% |
| Sep 30, 2021 | 18.17% |